CLGN and gastric cancer: Separate analysis of patients with gastric cancer and non–small cell lung cancer showed that all 4 of the analytes (CLGN, TXD15, HSPA5, and RCN1) were significantly increased in patients who developed clots in both gastric and non–small cell cancer cohorts (Figure 1D).